Clinical Trial

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Study acronym: CANARY
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-01-27; most recent amendment 2026-04-30.
Status change: Not Yet Recruiting → Recruiting 2025-01-29
Trial Details
NCT Number NCT05715814
Lead Sponsor University Health Network, Toronto
Conditions Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors, Kidney Dysfunction, Residual Kidney Function
Enrollment 20 participants
Start Date 2024-09-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-01